J Geiger

Summary

Country: Germany

Publications

  1. ncbi request reprint Inhibitors of platelet signal transduction as anti-aggregatory drugs
    J Geiger
    Institute for Clinical Biochemistry and Pathobiochemistry, Medical University Clinic, University of Wuerzburg, Germany
    Expert Opin Investig Drugs 10:865-90. 2001
  2. ncbi request reprint Monitoring of clopidogrel action: comparison of methods
    Jörg Geiger
    Institut für Klinische Biochemie und Pathobiochemie und Zentrallabor, Universitat Wurzburg, Wurzburg, Germany
    Clin Chem 51:957-65. 2005
  3. doi request reprint Insulin inhibition of platelet-endothelial interaction is mediated by insulin effects on endothelial cells without direct effects on platelets
    S Rauchfuss
    Institute of Clinical Biochemistry and Pathobiochemistry, University of Wurzburg, Wurzburg, Germany
    J Thromb Haemost 6:856-64. 2008
  4. ncbi request reprint Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects
    U R Schwarz
    Institute for Clinical Biochemistry and Pathobiochemistry, Medical University Clinic, Wurzburg, Germany
    Thromb Haemost 82:1145-52. 1999
  5. pmc Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice
    W Hauser
    Institut für Klinische Biochemie und Pathobiochemie und, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Proc Natl Acad Sci U S A 96:8120-5. 1999

Collaborators

  • S Gambaryan
  • M Eigenthaler
  • U Walter
  • S Rauchfuss
  • U R Schwarz
  • T Renne
  • W Hauser
  • V Krenn
  • M Zimmer
  • M Glazova
  • I Horak
  • E Rohde
  • K P Knobeloch

Detail Information

Publications5

  1. ncbi request reprint Inhibitors of platelet signal transduction as anti-aggregatory drugs
    J Geiger
    Institute for Clinical Biochemistry and Pathobiochemistry, Medical University Clinic, University of Wuerzburg, Germany
    Expert Opin Investig Drugs 10:865-90. 2001
    ..While several of the novel anti-aggregatory drugs were disappointing in clinical studies combinations of drugs with different effector enzymes showed potent antithrombotic efficacy...
  2. ncbi request reprint Monitoring of clopidogrel action: comparison of methods
    Jörg Geiger
    Institut für Klinische Biochemie und Pathobiochemie und Zentrallabor, Universitat Wurzburg, Wurzburg, Germany
    Clin Chem 51:957-65. 2005
    ..Because failure of antiplatelet therapy can have severe consequences, there is need for a reliable assay to quantify the effectiveness of clopidogrel treatment...
  3. doi request reprint Insulin inhibition of platelet-endothelial interaction is mediated by insulin effects on endothelial cells without direct effects on platelets
    S Rauchfuss
    Institute of Clinical Biochemistry and Pathobiochemistry, University of Wurzburg, Wurzburg, Germany
    J Thromb Haemost 6:856-64. 2008
    ..Here, acute effects of insulin on platelet activation and platelet-endothelial cell interactions were analyzed...
  4. ncbi request reprint Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects
    U R Schwarz
    Institute for Clinical Biochemistry and Pathobiochemistry, Medical University Clinic, Wurzburg, Germany
    Thromb Haemost 82:1145-52. 1999
    ..In a first clinical application, the inhibitory effects of ticlopidine and clopidogrel on the platelet P2YAC ADP receptor were monitored...
  5. pmc Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice
    W Hauser
    Institut für Klinische Biochemie und Pathobiochemie und, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Proc Natl Acad Sci U S A 96:8120-5. 1999
    ..VASP-deficient mice may provide an interesting model system for diseases in which enhanced platelet activation plays a major role...